Telix Pharmaceuticals (TLX) Non-Current Deferred Tax Liability (2024 - 2026)
Telix Pharmaceuticals (TLX) posted quarterly Non-Current Deferred Tax Liability of $44.7 million for Q4 2025, up 628.73% year-over-year from $6.1 million in Q4 2024, and up 628.73% quarter-over-quarter from $6.1 million in Q4 2024.
Powered by 
Analysis
Telix Pharmaceuticals (TLX) Non-Current Deferred Tax Liability (2024 - 2026) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $44.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability rose 628.73% year-over-year to $44.7 million; the TTM figure through Dec 2025 stood at $44.7 million (up 628.73% YoY), while the FY2025 annual figure was $44.7 million, up 671.33% from the prior year.
- Non-Current Deferred Tax Liability improved to $44.7 million in Q4 2025 per TLX's latest filing, from $6.1 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $44.7 million in Q4 2025 and bottomed at $6.1 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Telix Pharmaceuticals | 4.03 Bn | 3.74 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 43.30 Mn |
| Dec 31, 2025 | 44.71 Mn |
| Dec 31, 2024 | 6.13 Mn |